Alterity Therapeutics shares new ATH434 trial data at neurology meeting

April 22, 2026 7:25 AM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented additional analysis of its Phase 2 trial data for ATH434 in Multiple System ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found